FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000630185> ?p ?o ?g. }

• W2000630185 endingPage "92" @default.
• W2000630185 startingPage "83" @default.
• W2000630185 abstract "Background Epirubicin is a cytotoxic drug, widely used in patients with breast cancer, but its application is limited by its cardiotoxicity. Assessment of left ventricular (LV) ejection fraction (EF) is performed to demonstrate cardiac dysfunction. Because normal EF can mask LV impairment, the aim of this study was to evaluate whether deformation and rotation assessed using speckle-tracking echocardiography represent better markers of early epirubicin-induced cardiotoxicity. Methods Forty women with breast cancer (mean age, 51 ± 8 years), scheduled to be treated with epirubicin-based chemotherapy, were prospectively enrolled. All patients underwent conventional echocardiography, tissue velocity imaging, and speckle-tracking echocardiography to evaluate LV geometry and EF, S′, deformation (longitudinal, circumferential, and radial strain and strain rate), and rotation. Patients were reevaluated after the third and sixth cycles of epirubicin (mean cumulative dose, 268 ± 22 g/m2). Results After the sixth cycle of treatment, 14 patients (35%) had developed epirubicin-induced cardiotoxicity (a decrease in EF of ≥10% to an EF of <55%; group I), and 26 patients (65%) did not fulfill the criteria for cardiotoxicity (group II). In the entire study population, after the third cycle of epirubicin, there were reductions in diastolic and longitudinal function, but patients in group I had significantly lower S′, longitudinal strain, and longitudinal strain rate than those in group II. Although after the third cycle of treatment, radial and circumferential deformation and rotation remained unchanged, these parameters showed significant reductions after the sixth cycle of epirubicin. A decrease in longitudinal strain after the third cycle of epirubicin was the best independent and accurate predictor of cardiotoxicity after the completion of treatment. Conclusions Assessment of myocardial longitudinal deformation detects subclinical LV dysfunction and can predict further changes in EF and therefore can be used to monitor epirubicin-induced cardiotoxicity. Epirubicin is a cytotoxic drug, widely used in patients with breast cancer, but its application is limited by its cardiotoxicity. Assessment of left ventricular (LV) ejection fraction (EF) is performed to demonstrate cardiac dysfunction. Because normal EF can mask LV impairment, the aim of this study was to evaluate whether deformation and rotation assessed using speckle-tracking echocardiography represent better markers of early epirubicin-induced cardiotoxicity. Forty women with breast cancer (mean age, 51 ± 8 years), scheduled to be treated with epirubicin-based chemotherapy, were prospectively enrolled. All patients underwent conventional echocardiography, tissue velocity imaging, and speckle-tracking echocardiography to evaluate LV geometry and EF, S′, deformation (longitudinal, circumferential, and radial strain and strain rate), and rotation. Patients were reevaluated after the third and sixth cycles of epirubicin (mean cumulative dose, 268 ± 22 g/m2). After the sixth cycle of treatment, 14 patients (35%) had developed epirubicin-induced cardiotoxicity (a decrease in EF of ≥10% to an EF of <55%; group I), and 26 patients (65%) did not fulfill the criteria for cardiotoxicity (group II). In the entire study population, after the third cycle of epirubicin, there were reductions in diastolic and longitudinal function, but patients in group I had significantly lower S′, longitudinal strain, and longitudinal strain rate than those in group II. Although after the third cycle of treatment, radial and circumferential deformation and rotation remained unchanged, these parameters showed significant reductions after the sixth cycle of epirubicin. A decrease in longitudinal strain after the third cycle of epirubicin was the best independent and accurate predictor of cardiotoxicity after the completion of treatment. Assessment of myocardial longitudinal deformation detects subclinical LV dysfunction and can predict further changes in EF and therefore can be used to monitor epirubicin-induced cardiotoxicity." @default.
• W2000630185 created "2016-06-24" @default.
• W2000630185 creator A5011747612 @default.
• W2000630185 creator A5012181400 @default.
• W2000630185 creator A5035260825 @default.
• W2000630185 creator A5066761165 @default.
• W2000630185 creator A5082575085 @default.
• W2000630185 date "2014-01-01" @default.
• W2000630185 modified "2023-10-17" @default.
• W2000630185 title "Early Detection of Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer" @default.
• W2000630185 cites W148860973 @default.
• W2000630185 cites W1495679923 @default.
• W2000630185 cites W1602804702 @default.
• W2000630185 cites W1796787464 @default.
• W2000630185 cites W1961248591 @default.
• W2000630185 cites W1963780084 @default.
• W2000630185 cites W1969922785 @default.
• W2000630185 cites W1970029906 @default.
• W2000630185 cites W1980224521 @default.
• W2000630185 cites W1984763397 @default.
• W2000630185 cites W1985833818 @default.
• W2000630185 cites W1999206499 @default.
• W2000630185 cites W2015795623 @default.
• W2000630185 cites W2020747361 @default.
• W2000630185 cites W2031658240 @default.
• W2000630185 cites W2054181865 @default.
• W2000630185 cites W2054805807 @default.
• W2000630185 cites W2066377982 @default.
• W2000630185 cites W2076803848 @default.
• W2000630185 cites W2077615442 @default.
• W2000630185 cites W2082095383 @default.
• W2000630185 cites W2085131980 @default.
• W2000630185 cites W2097597389 @default.
• W2000630185 cites W2097985757 @default.
• W2000630185 cites W2101099004 @default.
• W2000630185 cites W2116917468 @default.
• W2000630185 cites W2120694824 @default.
• W2000630185 cites W2121981428 @default.
• W2000630185 cites W2124443610 @default.
• W2000630185 cites W2130683228 @default.
• W2000630185 cites W2131916402 @default.
• W2000630185 cites W2133475821 @default.
• W2000630185 cites W2133528707 @default.
• W2000630185 cites W2153038881 @default.
• W2000630185 cites W2157264444 @default.
• W2000630185 cites W2170514599 @default.
• W2000630185 cites W2170913861 @default.
• W2000630185 cites W2769648988 @default.
• W2000630185 cites W4211042579 @default.
• W2000630185 cites W4239462698 @default.
• W2000630185 cites W4245806444 @default.
• W2000630185 doi "https://doi.org/10.1016/j.echo.2013.10.008" @default.
• W2000630185 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24268372" @default.
• W2000630185 hasPublicationYear "2014" @default.
• W2000630185 type Work @default.
• W2000630185 sameAs 2000630185 @default.
• W2000630185 citedByCount "77" @default.
• W2000630185 countsByYear W20006301852014 @default.
• W2000630185 countsByYear W20006301852015 @default.
• W2000630185 countsByYear W20006301852016 @default.
• W2000630185 countsByYear W20006301852017 @default.
• W2000630185 countsByYear W20006301852018 @default.
• W2000630185 countsByYear W20006301852019 @default.
• W2000630185 countsByYear W20006301852020 @default.
• W2000630185 countsByYear W20006301852021 @default.
• W2000630185 countsByYear W20006301852022 @default.
• W2000630185 countsByYear W20006301852023 @default.
• W2000630185 crossrefType "journal-article" @default.
• W2000630185 hasAuthorship W2000630185A5011747612 @default.
• W2000630185 hasAuthorship W2000630185A5012181400 @default.
• W2000630185 hasAuthorship W2000630185A5035260825 @default.
• W2000630185 hasAuthorship W2000630185A5066761165 @default.
• W2000630185 hasAuthorship W2000630185A5082575085 @default.
• W2000630185 hasConcept C121608353 @default.
• W2000630185 hasConcept C126322002 @default.
• W2000630185 hasConcept C164705383 @default.
• W2000630185 hasConcept C2776694085 @default.
• W2000630185 hasConcept C2776802502 @default.
• W2000630185 hasConcept C2778198053 @default.
• W2000630185 hasConcept C2778233292 @default.
• W2000630185 hasConcept C2778296771 @default.
• W2000630185 hasConcept C2780835546 @default.
• W2000630185 hasConcept C530470458 @default.
• W2000630185 hasConcept C71924100 @default.
• W2000630185 hasConcept C78085059 @default.
• W2000630185 hasConceptScore W2000630185C121608353 @default.
• W2000630185 hasConceptScore W2000630185C126322002 @default.
• W2000630185 hasConceptScore W2000630185C164705383 @default.
• W2000630185 hasConceptScore W2000630185C2776694085 @default.
• W2000630185 hasConceptScore W2000630185C2776802502 @default.
• W2000630185 hasConceptScore W2000630185C2778198053 @default.
• W2000630185 hasConceptScore W2000630185C2778233292 @default.
• W2000630185 hasConceptScore W2000630185C2778296771 @default.
• W2000630185 hasConceptScore W2000630185C2780835546 @default.
• W2000630185 hasConceptScore W2000630185C530470458 @default.
• W2000630185 hasConceptScore W2000630185C71924100 @default.
• W2000630185 hasConceptScore W2000630185C78085059 @default.
• W2000630185 hasIssue "1" @default.

• next